Pea, Antonio https://orcid.org/0000-0002-0509-6756
He, Xiaotong https://orcid.org/0000-0003-4017-2037
Upstill-Goddard, Rosie
Luchini, Claudio https://orcid.org/0000-0003-4901-4908
Schubert Santana, Leonor Patricia
Dreyer, Stephan
Duthie, Fraser
Jamieson, Nigel B. https://orcid.org/0000-0002-9552-4725
McKay, Colin J.
Dickson, Euan J.
Pulvirenti, Alessandra https://orcid.org/0000-0001-9542-9165
Rebus, Selma
Piccoli, Paola
Sperandio, Nicola
Lawlor, Rita T. https://orcid.org/0000-0003-3160-0634
Milella, Michele
Froeling, Fieke E. M. https://orcid.org/0000-0002-8653-8164
Salvia, Roberto
Scarpa, Aldo https://orcid.org/0000-0003-1678-739X
Biankin, Andrew V. https://orcid.org/0000-0002-0362-5597
Wedge, David C. https://orcid.org/0000-0002-7572-3196
Chang, David K. https://orcid.org/0000-0002-4821-3078
Article History
Received: 5 January 2025
Accepted: 9 February 2026
First Online: 4 March 2026
Competing interests
: D.K.C. has received consulting and lecture fees from Immodulon Therapeutics and Mylan, research funding from Astrazeneca, BMS GmbH & Co. KG, Merck, and Immodulon Therapeutics. MM reports honoraria from AstraZeneca, MSD Oncology, Ipsen, Hippocrates, Viatris, and Servier, and reports consulting or advisory role for AstraZeneca, MSD Oncology, and Janssen Oncology; research funding from Roche and other relationships (participation to protocol Steering Committees and Independent Data Monitoring Committee) with Novartis and OncoSil. FEMF has received research funding from Astrazeneca and Sierra Oncology, speakers fees from Servier Oncology, Viatris travel support from Viatris, and is in the advisory board of Astellas and Abbott. NBJ has received honorariums and delivered talks for Nanostring, 10x genomics, APkoya, and is the scientific advisory board for Galvani. C.L. has received funds from NTP (scientific advisor), MSD (speaker bureau), and Medica srl (speaker bureau). No potential conflicts of interest were disclosed by the other authors.